financetom
Business
financetom
/
Business
/
India's Hindalco beats Q2 profit view on higher aluminium prices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India's Hindalco beats Q2 profit view on higher aluminium prices
Nov 11, 2024 6:18 AM

Nov 11 (Reuters) - India's Hindalco Industries

, one of the country's largest aluminium and copper

producers, posted a higher-than-expected second-quarter profit

on Monday, helped by higher aluminium prices.

The company, owned by the Aditya Birla Group, said its

consolidated net profit jumped 78% to 39.09 billion rupees

($463.3 million) for the three months ended Sept. 30, beating

estimates.

Analysts, on average, had expected a profit of 34.46 billion

rupees, according to data compiled by LSEG.

($1 = 84.3700 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru; Editing by Sumana

Nandy and Abinaya Vijayaraghavan)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO
BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO
Nov 3, 2024
Oct 30 (Reuters) - Polyrizon Ltd ( PLRZ ): * POLYRIZON ANNOUNCES CLOSING OF $4.2 MILLION INITIAL PUBLIC OFFERING Source text: Further company coverage: ...
Bancfirst Corp Insider Sold Shares Worth $567,500, According to a Recent SEC Filing
Bancfirst Corp Insider Sold Shares Worth $567,500, According to a Recent SEC Filing
Nov 3, 2024
11:08 AM EDT, 10/30/2024 (MT Newswires) -- William Scott Martin, Director, on Oct. 30, 2024, sold 5,000 shares in Bancfirst Corp ( BANF ) for $567,500. Following the Form 4 filing with the SEC, Martin has control over a total of 306,904 shares of the company, with 306,904 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/760498/000159396824001319/xslF345X05/primary_01.xml Price: 112.39, Change: +1.68, Percent Change: +1.52...
Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease
Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease
Nov 3, 2024
11:04 AM EDT, 10/30/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Wednesday it has seen positive interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease. Treatment with the gene therapy candidate resulted in dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive...
Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy
Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy
Nov 3, 2024
11:06 AM EDT, 10/30/2024 (MT Newswires) -- Tharimmune ( THAR ) shares climbed by more than 130% in recent Wednesday trading after the company said it received positive feedback from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC. The feedback came in a Scientific Advice meeting, the company said, where...
Copyright 2023-2026 - www.financetom.com All Rights Reserved